CYP4F2 and neoplasm: In poor-prognosis luminal A tumours, for example, overexpression of CYP4F2 can metabolically suppress T-cell function, thereby undermining immune surveillance and facilitating immune evasion even in the presence of a favourable WWOX/HIF1A ratio.